News

Home>News
News2020-07-17T11:41:26-04:00
Nov 22020

Halberd Corp. CEO Interviewed on Money TV

November 2nd, 2020|Categories: Featured, Investor News, News, Videos|

In Case You Missed It - Mr. Hartman discusses recent accomplishments and new opportunities. Jackson Center, PA, November 2, 2020 – Halberd Corporation (OTC-PINK: "HALB") Chairman, President and CEO, William A. Hartman, was interviewed recently by host, Donald Baillargeon, on Money TV. In the segment, Mr. Hartman provided an update on the company’s latest activities, and new efforts underway. Mr. Baillargeon began the interview by asking how Halberd decided on its university research partner.  Mr. ...

Oct 292020

Halberd Corp. Development Efforts Transcend Covid-19 Prevention, Diagnostics & Therapeutics

October 29th, 2020|Categories: Featured, Investor News, News|

Jackson Center, PA, October 29, 2020 – Halberd Corporation (OTC PINK: "HALB") today provided insight concerning its strategic plans beyond developing unique antibodies which form the basis of their current all-out efforts to generate products and processes to prevent, diagnose and treat Covid-19.  These strategic plans are designed to benefit people well after Covid-19 is no longer an issue. William A. Hartman, Halberd Corporation Chairman, President & CEO, stated, “Currently, we are dedicating our maximum ...

Oct 272020

Halberd Corp. Retains Prestigious Patent Law Firm on Covid-19-Related and Other Disease Technologies

October 27th, 2020|Categories: Featured, Investor News, News|Tags: , , , , |

Jackson Center, PA, October 27, 2020 – Halberd Corporation (OTC PINK: "HALB") has retained the services of a prestigious Pittsburgh, PA law firm, Ference & Associates, to handle its intellectual property matters.  The initial application focuses on patenting Halberd’s base Covid-19 antibody as well as an entire new class of antibody conjugate. The primary attorney on the Halberd account is Dr. Darwin King, Esq., who has extensive experience in dealing with intellectual property matters in ...

Oct 262020

ICYMI — Halberd Corporation Discusses The Development of New Class of COVID-19 Antibody with The Stock Day Podcast

October 26th, 2020|Categories: Featured, Investor News, News|Tags: , , , , |

In Case You Missed It Phoenix, Arizona–(Newsfile Corp. – October 22, 2020) – The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB) (“the Company”), a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. CEO of the Company, Bill Hartman, joined Stock Day host Everett Jolly. Jolly began the interview by asking about Hartman’s transition from his former position as the CEO of Premier Biomedical to ...

Oct 192020

Arizona State University/Halberd Initiate Patent Application for Unique New Engineered Class of Covid-19 Antibody

October 19th, 2020|Categories: Featured, Investor News, News|Tags: , , , , , |

Updated 12:30PM Jackson Center, PA, October 19, 2020 – Halberd Corporation (OTC PINK: "HALB") today announced the creation of a new class of anti-Spike protein monoclonal antibodies against Covid-19.  The discovery is the result of Halberd’s research in conjunction with Arizona State University’s Dr. Qiang “Shawn” Chen, utilizing Halberd’s intellectual property created by Mitchel S. Felder, MD.  Halberd and ASU have begun the process of filing the first of multiple planned joint patent applications for ...

Oct 132020

Arizona State University/Halberd Develop Antibody Against Covid-19

October 13th, 2020|Categories: Featured, Investor News, News|Tags: , , , , , |

Jackson Center, PA, October 13, 2020 – Halberd Corporation (OTC PINK: "HALB") reported that Arizona State University researchers, utilizing the intellectual property of Halberd Corporation, have successfully generated an anti-Spike protein monoclonal antibody against Covid-19.  The Spike Protein is a main component of the Covid-19 virus, and is a crucial component in its ability to replicate.  In addition, the researchers have sent for synthesis, genes for the creation of new, unique monoclonal antibodies against the SARS-CoV-2 Spike ...

Go to Top